BRTX

BioRestorative Therapies Inc

Add to Watchlist

Advanced Chart

1.410

-0.06(-4.082%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.410

Open

1.410

VWAP

1.41

Vol

400.00

Mkt Cap

11.73M

Low

1.410

Amount

564.00

EV/EBITDA(TTM)

Total Shares

6.77M

4.36M

EV/OCF(TTM)

P/S(TTM)

19.97

BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.

Intellectia.AI: Your Edge in Stock Trading

Join 300K+ users and access AI-powered stock picks that spot trends in minutes!

Intellectia.AI: Your Edge in Stock Trading

Join 300K+ users and access AI-powered stock picks that spot trends in minutes!

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

340.00K

+281.59%

410.00K

+75.51%

470.00K

+985.45%

Estimates Revision

The market is revising Upward the revenue expectations for BioRestorative Therapies, Inc. (BRTX) for FY2025, with the revenue forecasts being adjusted by 34.59% over the past three months. During the same period, the stock price has changed by -17.75%.

Revenue Estimates for FY2025

Revise Upward

+34.59%

In Past 3 Month

Stock Price

Go Down

-17.75%

In Past 3 Month

2 Analyst Rating

821.99% Upside

Wall Street analysts forecast BRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRTX is 13.00 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

821.99% Upside

Current: 1.410

Low

8.00

Averages

13.00

High

18.00

821.99% Upside

Current: 1.410

Low

8.00

Averages

13.00

High

18.00

Roth MKM

Jonathan Aschoff

Strong Buy

Maintains

$15 → $18

2024-08-14

Reason

Roth MKM

Jonathan Aschoff

Price Target

$15 → $18

2024-08-14

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for BioRestorative Therapies Inc (BRTX.O) is -1.10, compared to its 5-year average forward P/E of -1.74. For a more detailed relative valuation and DCF analysis to assess BioRestorative Therapies Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.74

Current PE

-1.10

Overvalued PE

0.51

Undervalued PE

-3.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

178.93

Current PS

6.27

Overvalued PS

414.22

Undervalued PS

-56.35

Intellectia.AI: Fast-Track Your Stock Wins

Loved by 300K+ users. Get precise AI signals to ride market trends in minutes!

Intellectia.AI: Fast-Track Your Stock Wins

Loved by 300K+ users. Get precise AI signals to ride market trends in minutes!

Financials

Annual

Quarterly

FY2025Q2

YoY :

+240.40%

303.30K

Total Revenue

FY2025Q2

YoY :

+33.88%

-3.31M

Operating Profit

FY2025Q2

YoY :

-100.00%

N/A

Net Income after Tax

FY2025Q2

YoY :

-40.00%

-0.30

EPS - Diluted

FY2025Q2

YoY :

+41.75%

-2.69M

Free Cash Flow

FY2025Q2

YoY :

+4.75%

97.12

Gross Profit Margin - %

FY2025Q2

YoY :

-60.81%

-1.59K

FCF Margin - %

FY2025Q2

YoY :

-80.63%

-875.79

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

1.8K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

1.8K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Trade Smarter with Intellectia.AI

300K+ trust us for AI trading signals that capture market momentum early!

Trade Smarter with Intellectia.AI

300K+ trust us for AI trading signals that capture market momentum early!

BRTX News & Events

Events Timeline

2025-06-17 (ET)

2025-06-17

09:26:36

BioRestorative Therapies announces $2M share repurchase program

2025-06-13 (ET)

2025-06-13

07:48:33

BioRestorative Therapies reports preliminary data from Phase 2 trial of BRTX-100

2025-06-10 (ET)

2025-06-10

08:11:49

BioRestorative Therapies appoints Sandy Lipkins for business development

News

9.5

08-12NASDAQ.COM

Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates

9.5

08-05Newsfilter

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

1.0

06-18Newsfilter

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates